Ein Labormitarbeiter bei der Arbeit (Symbolbild).
Montag, 16.01.2017 13:00 von | Aufrufe: 85

SHIRE PLC - Director/PDMR Shareholding

Ein Labormitarbeiter bei der Arbeit (Symbolbild). © Totojang / iStock / Getty Images Plus / Getty Images

PR Newswire

Director/PDMR Shareholding

January 16, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”)

Notification of transactions by person discharging managerial responsibilities

1. Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a) Name Jeff Poulton
2. Reason for the notification
a) Position / status Chief Financial Officer – PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares (“ADSs”)
Identification code ISIN: US82481R1068
b) Nature of the transaction Acquisition of ADSs following the automatic re-investment of dividends received, as paid to shareholders on April 14, 2015. Mr. Poulton became aware of the transaction on January 13, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
$246.6702 3.904241
d) Aggregated information N/A (single transaction)
e) Date of the transaction April 14, 2015
f) Place of the transaction NASDAQ Global Select Market
5. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares (“ADSs”)
Identification code ISIN: US82481R1068
b) Nature of the transaction Acquisition of ADSs following the automatic re-investment of dividends received, as paid to shareholders on October 2, 2015. Mr. Poulton became aware of the transaction on January 13, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
$205.13 1.037245
d) Aggregated information N/A (single transaction)
e) Date of the transaction October 2, 2015
f) Place of the transaction NASDAQ Global Select Market
6. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares (“ADSs”)
Identification code ISIN: US82481R1068
b) Nature of the transaction Acquisition of ADSs following the automatic re-investment of dividends received, as paid to shareholders on April 12, 2016. Mr. Poulton became aware of the transaction on January 13, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
$180.3824 6.468702
d) Aggregated information N/A (single transaction)
e) Date of the transaction April 12, 2016
f) Place of the transaction NASDAQ Global Select Market
7. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares (“ADSs”)
Identification code ISIN: US82481R1068
b) Nature of the transaction Acquisition of ADSs following the automatic re-investment of dividends received, as paid to shareholders on October 7, 2016. Mr. Poulton became aware of the transaction on January 13, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
$193.77 1.262528
d) Aggregated information N/A (single transaction)
e) Date of the transaction October 7, 2016
f) Place of the transaction NASDAQ Global Select Market

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874

Media
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Debbi Ford debbi.ford@shire.com  +1 617 949 9083

NOTES TO EDITORS

About Shire


ARIVA.DE Börsen-Geflüster

Kurse

-  
0,00%
Shire Chart
-  
0,00%
Shire ADR Chart

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com

Werbung

Mehr Nachrichten zur Shire ADR Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.